Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00322673
Status:
TERMINATED
Last Update Posted:
2010-02-22
First Post:
2006-05-04
Brief Title:
Study of XL999 in Patients With Acute Myeloid Leukemia AML
Sponsor:
Symphony Evolution Inc
Organization:
Symphony Evolution Inc
Study Overview
Official Title:
A Phase 2 Study of XL999 Administered Intravenously to Subjects With Acute Myeloid Leukemia
Status:
TERMINATED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was terminated due to cardiac toxicities
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical study is being conducted at multiple sites to determine the activity safety and tolerability of XL999 when given weekly to patients with relapsed or newly-diagnosed AML XL999 is a small molecule inhibitor against Flk1kinase insert domain receptor KDR PDGFR c-Kit FLT3 and SRC c-Kit and FLT3 are receptors commonly expressed on AML blasts
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None